Novel peptides that inhibit heparanase activation of the coagulation system

Thrombosis and Haemostasis

Volumn 112, Issue 3, 2014, Pages 466-477

  Axelman, Elena ^a   Henig, Israel ^a   Crispel, Yonatan ^a   Attias, Judith ^b   Li, Jin Ping ^c   Brenner, Benjamin ^a   Vlodavsky, Israel ^d   Nadir, Yona ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Stat Laboratory   (Israel)

^c UPPSALA UNIVERSITY   (Sweden)

^d Cancer and Vascular Biology Research Center   (Israel)

Author keywords

Anticoagulant; Heparanase; Peptides; TFPI 2; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; HEPARANASE; INTERLEUKIN 6; PROCOAGULANT; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; BETA GLUCURONIDASE; BLOOD CLOTTING FACTOR 10; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; GLYCOPROTEIN; LIPOPOLYSACCHARIDE; PEPTIDE FRAGMENT; THROMBIN; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE SEVERITY; DNA TRANSFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; SEPSIS; THROMBOELASTOGRAPHY; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFERIOR CAVA VEIN; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FACTOR X; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GLUCURONIDASE; GLYCOPROTEINS; HEK293 CELLS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; THROMBIN; THROMBOPLASTIN; THROMBOSIS; VENA CAVA, INFERIOR;

EID: 84933055934     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-12-1049     Document Type: Article

References (21)

1. Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-1350.
2. Pikas DS, Li JP, Vlodavsky I, et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-1877.
3. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: M99-108.
4. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-347.
5. Nadir Y, Brenner B, Zetser A, et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4: 2443-2451.
6. Nadir Y, Brenner B, Gingis-Velitski S, et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 2008; 99: 133-141.
7. Nadir Y, Brenner B, Fux L, et al. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95: 1927-1934.
8. Baker AB, Gibson WJ, Kolachalama VB, et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol 2012; 59: 1551-1560.
9. Zcharia E, Metzger S, Chajek-Shaul T, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-263.
10. Zcharia E, Jia J, Zhang X, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009; 4: e5181.
11. Diaz JA, Obi AT, Myers DD, Jr., et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 556-562.
12. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-2258.
13. Ahamed J, Niessen F, Kurokawa T, et al. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood 2007; 109: 5251-5259.
14. Sprecher CA, Kisiel W, Mathewes S, et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-3357.
15. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2 Suppl): S26-34.
16. Nadir Y, Kenig Y, Drugan A, et al. Involvement of heparanase in vaginal and cesarean section deliveries. Thromb Res 2010; 126: e444-450.
17. Nadir Y, Kenig Y, Drugan A, et al. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011; 128: e3-8.
18. Westergaard JG, Teisner B, Hau J, et al. Placental protein and hormone measurements in twin pregnancy. Br J Obstet Gynaecol 1985; 92: 72-76.
19. Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994; 84: 4384-4385.
20. Vlodavsky I, Elkin M, Abboud-Jarrous G, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 2008; 49: 207-210.
21. Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004; 103: 1069-1077.